Journal: Translational Oncology

Article Title: Piperlongumine suppresses YAP-ET-1-CXCL2 signaling to modulates aggressiveness of triple-negative breast cancer cells

doi: 10.1016/j.tranon.2026.102700

Figure Lengend Snippet: Piperlongumine (PL) inhibits YAP signaling in triple-negative breast cancer (TNBC) cells. (A) Western blot analysis of YAP protein levels in MDA-MB-231 and BT549 cells treated with PL (0, 1, and 5 μ M) for 24 h. (B) Western blot analysis of YAP and phosphorylated YAP (p-YAP) expression treated with PL in different time points. (C) Western blot analysis of phosphorylated LATS (p-LATS) and phosphorylated AMPK (p-AMPK) at different time points after PL treatment. (D) Representative immunofluorescence images of YAP expression in BT549 and MDA-MB-231 cells treated with PL for 24 h at the indicated concentrations, with quantification of nuclear YAP-positive cells. Scale bar, 50 μ m. * p < 0.05 and ** p < 0.01, as determined by unpaired t -tests.

Article Snippet: Antibodies for YAP (#12395), phosphorylated (p)-YAP (S127) (#13008), p-YAP (S61) (#75784), p-AMPK (AMPK; #130429), AMPK (#103487), p-LATS1 (S909) (#9157), and LATS1 (#3477) were purchased from Cell Signaling Technology.

Techniques: Western Blot, Expressing, Immunofluorescence